NasdaqCM - Delayed Quote USD

Aldeyra Therapeutics, Inc. (ALDX)

3.9400 +0.0300 (+0.77%)
At close: April 24 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Todd C. Brady M.D., Ph.D. CEO, President & Director 834.1k -- 1972
Dr. Stephen G. Machatha Ph.D. Chief Development Officer 503.62k -- 1977
Mr. Kelly Mizer Vice President of Commercial Strategy & Operations -- -- --
David Burke Head of Investor Relations -- -- --

Aldeyra Therapeutics, Inc.

131 Hartwell Avenue
Suite 320
Lexington, MA 02421
United States
781 761 4904 https://www.aldeyra.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
10

Description

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Corporate Governance

Aldeyra Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024 - May 06, 2024
Aldeyra Therapeutics, Inc. Earnings Call

Related Tickers

ARDX Ardelyx, Inc.
6.43
+0.63%
 
MCRB Seres Therapeutics, Inc.
0.7295
-4.01%
 
ALXO ALX Oncology Holdings Inc.
16.22
+4.65%
 
SNDX Syndax Pharmaceuticals, Inc.
20.79
-0.86%
 
LVTX LAVA Therapeutics N.V.
2.7400
-8.05%
 
ADMA ADMA Biologics, Inc.
6.46
-1.22%
 
IKT Inhibikase Therapeutics, Inc.
1.8700
+18.35%
 
FGEN FibroGen, Inc.
0.9843
-8.01%
 
ACET Adicet Bio, Inc.
1.8750
-10.71%
 
EFTR eFFECTOR Therapeutics, Inc.
1.8500
-4.64%